$0.13
4.00% yesterday
Nasdaq, May 20, 10:18 pm CET
ISIN
US45674E1091
Symbol
INAB
Sector
Industry

IN8bio Inc Stock price

$0.13
-0.04 21.78% 1M
-0.19 59.56% 6M
-0.13 49.46% YTD
-0.89 87.25% 1Y
-2.06 94.06% 3Y
-9.87 98.70% 5Y
-9.87 98.70% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.01 4.00%
ISIN
US45674E1091
Symbol
INAB
Sector
Industry

Key metrics

Market capitalization $11.80m
Enterprise Value $4.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.76
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-26.61m
Free Cash Flow (TTM) Free Cash Flow $-19.47m
Cash position $11.89m
EPS (TTM) EPS $-0.49
P/E forward negative
Short interest 0.63%
Show more

Is IN8bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

IN8bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a IN8bio Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a IN8bio Inc forecast:

Buy
100%

Financial data from IN8bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 2.45 2.45
4% 4%
-
-2.45 -2.45
4% 4%
-
- Selling and Administrative Expenses 6.68 6.68
23% 23%
-
- Research and Development Expense 15 15
13% 13%
-
-24 -24
15% 15%
-
- Depreciation and Amortization 2.45 2.45
4% 4%
-
EBIT (Operating Income) EBIT -27 -27
14% 14%
-
Net Profit -27 -27
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about IN8bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IN8bio Inc Stock News

Neutral
GlobeNewsWire
7 days ago
Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γ...
Neutral
GlobeNewsWire
9 days ago
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio's proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune c...
Neutral
GlobeNewsWire
13 days ago
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meetings On May 1 st , 2025, we celebrated the 5 th anniversary of the first patient ever treated wi...
More IN8bio Inc News

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Head office United States
CEO William Ho
Employees 18
Founded 2016
Website www.in8bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today